The Japanese Journal of Antibiotics
Online ISSN : 2186-5477
Print ISSN : 0368-2781
ISSN-L : 0368-2781
Volume 60, Issue 5
Displaying 1-4 of 4 articles from this issue
  • KATSUNORI YANAGIHARA, YOSHITOMO MORINAGA, KAZUKO FUKUSHIMA, SHIGEKI NA ...
    2007 Volume 60 Issue 5 Pages 251-256
    Published: October 25, 2007
    Released on J-STAGE: May 17, 2013
    JOURNAL FREE ACCESS
    Recently, proper use of antimicrobial agents for treatment of infections based on pharmacokinetics (PK) /pharmacodynamics (PD) theory has been recommended to many clinical doctors.
    To consider the optimized administration method based on PK/PD theory for the elderly patients of gatifloxacin (GFLX), which was one of the oral respiratory quinolone antibacterial, Monte Carlo Simulation was conducted with community-acquired pneumonia and susceptibility data for Streptococcus pneumoniae (345 strains) collected by the second gatifloxacin surveillance study.
    From this results, the probabilities of achieving AUC/MIC 30 against pneumococcus for the elderly patients was 96.3% at twice-daily dosing of GFLX 100 mg, 97.2% at twice-daily dosing of GFLX 200 mg, therefore, it was suggested that the clinical effectiveness of the regimen of GFLX 100 mg was as well as the regimen of GFLX 200 mg.
    Download PDF (3051K)
  • HIROSHI SAKATA
    2007 Volume 60 Issue 5 Pages 257-263
    Published: October 25, 2007
    Released on J-STAGE: May 17, 2013
    JOURNAL FREE ACCESS
    Between October 2006 and April 2007, we enrolled 90 children with group A streptococcal infection in a prospective multicenter study. Children aged from 8 months to 12 years (6.2±2.2 years) treated with cefditoren pivoxil 9 mg/kg/day tid for 7 days were evaluated for clinical efficacy and bacterial effect at the end of therapy and were observed for the occurrence of recurrent infection and complications 4 weeks after the end of therapy. The most frequent T-types of 90 isolates were Ti, T28, and T12 at 50.0%, 21.1, and 11.1%.
    Of the 90, 11 did not return for follow-up. The 79 we evaluated clinical efficacy and their symptoms were ameliorated. Four still had GAS from pharyngeal swabs at the end of therapy. Isolates from them were identical to initial strains in T-type and PFGE pattern.
    All 78 observed within 1 month after the end of administration had no complications, but 5 had a recurrence of GAS infection. Two still had GAS from pharyngeal swabs at the end of therapy. Isolates from recurrence cases were identical to initial strains in T-type and PFGE pattern. Adverse effects were diarrhea observed in 1.
    Download PDF (7432K)
  • 2007 Volume 60 Issue 5 Pages 265-307
    Published: October 25, 2007
    Released on J-STAGE: May 17, 2013
    JOURNAL FREE ACCESS
    Download PDF (5273K)
  • 2007 Volume 60 Issue 5 Pages 311-318
    Published: October 25, 2007
    Released on J-STAGE: May 17, 2013
    JOURNAL FREE ACCESS
    Download PDF (7254K)
feedback
Top